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Long term protection against invasive meningococcal disease relies on persistence of bactericidal anti-
bodies. We studied the persistence of serum bactericidal antibodies using rabbit and human complement
(rSBA, hSBA assays) two years after vaccination with a meningococcal serogroup A, C, W, Y tetanus toxoid
conjugate vaccine (MenACWY-TT, N = 253) or a licensed monovalent serogroup C conjugate vaccine
(MenC-CRM197, N = 42) in Finnish toddlers who were aged 12–23 months at the time of vaccination. In
97.8–98.9% of subjects receiving MenACWY-TT, rSBA titres P1:8 persisted against serogroups A, W
and Y and 88.2% against serogroup C, which was according to exploratory analysis statistically signiﬁ-
cantly higher than in recipients of the MenC-CRM197 vaccine (69.0%). A total of 86.9% of subjects had per-
sisting hSBAP1:8 for serogroup C, which was statistically signiﬁcantly higher than the MenC-CRM group
(52.6%). Exploratory analysis also showed that the year 2 hSBA-MenC geometric mean titre was statisti-
cally signiﬁcantly higher in the MenACWY-TT group than the MenC-CRM group. At least 87.0% of subjects
had hSBAP1:8 for serogroups W and Y at year 2, while the percentage was 23.0% for serogroup A. Using
rSBA, but not hSBA, a high percentage of MenC-CRM197 recipients acquired antibody against serogroups A
(82.1%), W (58.6%) and Y (80.0%). MenACWY-TT induced high level of bactericidal antibody in toddlers
that persisted for at least 2 years.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The highest incidence of invasive meningococcal disease occurs
in infants followed by young children [1–3]. Monovalent serogroup
C (MenC) conjugate vaccines have been successfully used to pre-
vent invasive meningococcal disease in infants, toddlers and indi-
viduals up to 18 years of age since 1999 [4]. The duration of
protection afforded by vaccination is not yet known, although evi-
dence from children who experienced vaccine failure suggests that
circulating antibody is needed for protection against invasive dis-
ease [5]. We previously demonstrated that a quadrivalent menin-
gococcal conjugate vaccine with four serogroup polysaccharides,
A, C, W and Y, all conjugated to tetanus toxoid (MenACWY-TT),
administered to toddlers, induced high levels of bactericidal anti-
bodies to serogroup A, W, and Y and was non-inferior to licensed
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CRM197) in terms of seroresponse to serogroup C [6]. We subse-
quently studied antibody persistence against each serogroup two
years after primary vaccination, using serum bactericidal assays
with either rabbit (rSBA) or human (hSBA) complement. Demon-
stration of a serological correlate of protection for serogroup C
was done using rSBA in post-licensure effectiveness studies [7,8],
whereas hSBA titres P1:4 are considered protective for serogroup
C [9].
Methods
In the primary vaccination study in Finland (www.clinicaltri-
als.gov NCT00474266), 12–23 month old toddlers randomised to
receive primary vaccination with MenACWY-TT (containing 5 lg
of each meningococcal serogroup A, C, W and Y polysaccharide
conjugated to tetanus toxoid: N = 749), or MenC-CRM197
(Meningitec™ Pﬁzer Inc., containing 10 lg of MenC polysaccharide
conjugated to mutant diphtheria toxoid CRM protein: N = 251) [6].
All children were invited to participate in the assessment of
antibody persistence at year 2 (NCT00955682). Children were not
allowed to participate if they had developed meningococcal
disease or received any meningococcal vaccination since the
primary vaccination study, or if they had an intervening
immunocompromising condition, or had received immunoglobulin
or blood products within 3 months of the study visit.
The protocol and associated documents were reviewed and
approved by the ethics committee of Pirkanmaa Hospital District.
Written informed consent was obtained from the parents/guard-
ians of children before study procedures were performed.
Bactericidal activity was assessed at GlaxoSmithKline Vaccines’
laboratory using a serum bactericidal assay with rabbit and human
complement (rSBA, hSBA, respectively) as previously described
[10]. The assay cut-offs were 1:8 for rSBA and 1:4 for hSBA. For
rSBA and hSBA we also considered more conservative thresholds65 eliminated: not eligible (2); 
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Fig. 1. Subject ﬂow. ⁄Mean age (standard deviation); F = female, M = male. N = num
TT + MMRV = subjects vaccinated with MenACWY-TT co-administered with MMRV; Men
MMRV; MMRV?MenC-CRM = subjects vaccinated with MMRV and 42 days later with
42 days later with MMRV. Persistence study: MenACWY-TT = subjects previously prime
and MenACWY-TT?MMRV groups. MenC-CRM197 = subjects previously primed with M
and MenC-CRM?MMRV groups.of 1:128 and 1:8, respectively. An hSBA titre P1:4 was demon-
strated to correlate with protection in humans who developed nat-
ural immunity to serogroup C [9]. A rSBA titre ofP1:8 was shown
to correlate with protection in populations vaccines with monova-
lent serogroup C vaccines [7,11]. It is common practice to extend
these thresholds to the other vaccine serogroups.
The primary objective was to assess the percentage of subjects
with rSBA antibody titres P1:8 for each of the four serogroups.
Evaluation of antibody persistence using hSBA was a secondary
objective.
Serious adverse events (SAEs) considered by the investigator to
be related to study procedures or GlaxoSmithKline concomitant
medication were captured retrospectively at the year 2 study visit.
An exploratory evaluation of the differences at each time point
was performed for the percentage of subjects with rSBA-MenC
antibody titres P1:8 and P1:128 and hSBA-MenC antibody titres
P1:4 and P1:8 with standardised asymptotic 95% CIs and the
ratio of the rSBA-MenC and hSBA-MenC GMTs with 95% CIs
between the MenACWY-TT and MenC-CRM groups. A statistically
signiﬁcant difference was indicated if the value ‘1’ was excluded
from the 95% CI on the GMT ratios or if the value ‘0’ was excluded
from the 95% CI on differences between groups. Note that potential
differences should be interpreted with caution considering that
there was no adjustment for multiplicity for these comparisons.
Statistical analyses were performed using SAS software version
9.2 (SAS Institute Inc., Cary, NC, United States) and ProcStatXact
8.1.
Results
The year 2 follow-up study took place between 25 August and
16 December 2009. There were 295 subjects who returned at year
2 (253 in the MenACWY-TT group and 42 in the MenC-CRM group).
Of these, 218 subjects contributed to the According-to-protocol
persistence cohort (Fig. 1). The median time since the primaryMMRV→MenC-CRM
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Table 1
rSBA and hSBA antibody persistence 42 days and 2 years after vaccination with MenACWY-TT or MenC-CRM197 at 12–23 months of age (According-to-protocol cohort for
persistence at Year 2).
Serogroup MenACWY-TT MenC-CRM197
rSBA N % P1:8 [95% CI] % P1:128 [95% CI] GMT [95% CI] N % P1:8 % [95% CI] % P1:128 [95% CI] GMT [95% CI]
A M1 186 100 [98.0; 100] 100 [98.0; 100] 1924 [1698; 2181] 14 50.0 [23.0; 77.0] 28.6 [8.4; 58.1] 22 [7; 66]
Y2 181 97.8 [94.4; 99.4] 91.7 [86.7; 95.3] 420 [356; 496] 28 82.1 [63.1; 93.9] 57.1 [37.2; 75.5] 91 [46; 178]
C M1 184 100 [98.0; 100] 94.0 [89.6; 97.0] 447 [397; 503] 30 93.3 [77.9; 99.2] 60.0 [40.6; 77.3] 146 [84; 255]
Y2 186 88.2 [82.6; 92.4] 48.4 [41.0; 55.8] 98 [78; 124] 29 69.0 [49.2; 84.7] 48.3 [29.4; 67.5] 54 [26; 112]
W M1 186 100 [98.0; 100] 100 [98.0; 100] 2241 [1999; 2512] 16 50.0 [24.7; 75.3] 18.8 [4.0; 45.6] 22 [7; 65]
Y2 188 98.9 [96.2; 99.9] 91.0 [85.9; 94.6] 397 [342; 461] 29 58.6 [38.9; 76.5] 41.4 [23.5; 61.1] 42 [19; 96]
Y M1 185 100 [98.0; 100] 100 [98.0; 100] 2550 [2213; 2937] 16 75.0 [47.6; 92.7] 56.3 [29.9; 80.2] 88 [30; 262]
Y2 188 97.9 [94.6; 99.4] 81.9 [75.7; 87.1] 397 [324; 486] 30 80.0 [61.4; 92.3] 66.7 [47.2; 82.7] 151 [69; 331]
hSBA N % P1:4 [95% CI] % P1:8 [95% CI] GMT [95% CI] N % P1:4 % [95% CI] % P1:8 [95% CI] GMT [95% CI]
A M1 179 83.2 [76.9; 88.4] 81.0 [74.5; 86.5] 23.2 [18.7; 28.7] 23 0.0 [0.0; 14.8] 0.0 [0.0; 14.8] 2.0 [2.0; 2.0]
Y2 183 25.1 [19.0; 32.1] 23.0 [17.1; 29.7] 3.8 [3.2; 4.5] 23 8.7 [1.1; 28.0] 0.0 [0.0; 14.8] 2.2 [1.9; 2.4]
C M1 179 98.3 [95.2; 99.7] 98.3 [95.2; 99.7] 170.2 [143.4; 202.0] 23 82.6 [61.2; 95.0] 82.6 [61.2; 95.0] 45.9 [21.0; 100.1]
Y2 175 88.0 [82.2; 92.4] 86.9 [80.9; 91.5] 50.2 [38.7; 65.1] 19 57.9 [33.5; 79.7] 52.6 [28.9; 75.6] 10.4 [4.7; 22.8]
W M1 176 81.8 [75.3; 87.2] 81.3 [74.7; 86.7] 42.1 [32.4; 54.7] 23 4.3 [0.1; 21.9] 4.3 [0.1; 21.9] 2.3 [1.8; 2.9]
Y2 180 92.8 [88.0; 96.1] 91.1 [86.0; 94.8] 77.7 [61.8; 97.6] 23 0.0 [0.0; 14.8] 0.0 [0.0; 14.8] 2.0 [2.0; 2.0]
Y M1 169 79.3 [72.4; 85.1] 79.3 [72.4; 85.1] 29.5 [22.8; 38.1] 23 4.3 [0.1; 21.9] 4.3 [0.1; 21.9] 2.5 [1.6; 4.1]
Y2 154 87.0 [80.7; 91.9] 87.0 [80.7; 91.9] 58.1 [44.5; 75.8] 22 22.7 [7.8; 45.4] 22.7 [7.8; 45.4] 5.0 [2.2; 11.1]
M1 = 42 days after vaccination; Y2 = 2 years after vaccination; N = number of subjects with available results. Note that in the case of insufﬁcient sera, not all assays were able
to be performed; 95% CI = 95% conﬁdence interval.
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ment groups were similar in terms of age and gender (Fig. 1).
rSBA antibodies
Two years after primary vaccination, 97.8–98.9% of subjects in
the MenACWY-TT group had persisting rSBA antibody titres P1:8
for serogroups A, W and Y, and 88.2% for serogroup C (Table 1).Fig. 2. Reverse cumulative curves for rSBA titres at pre- and post-vacciFor each serogroup, rSBA GMTs decreased by year 2 but remained
higher than pre-vaccination levels (Table 1 and Fig. 2).
The percentage of subjects in the MenC-CRM group with
serogroup C rSBA titresP1:8 was 69.0% (Table 1). The rSBA-MenC
GMT decreased by year 2 but remained higher than pre-
vaccination levels (Table 1 and Fig. 2).
The exploratory group comparison indicated that antibody
persistence for serogroup C was signiﬁcantly higher in thenation and at year 2 (M24) (ATP cohort for persistence at year 2).
Fig. 3. Reverse cumulative curves for hSBA titres at pre- and post-vaccination and at year 2 (M24) (ATP cohort for persistence at year 2).
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the percentage of subjects with rSBA titres P1:8. No statistically
signiﬁcant differences between groups were observed for the per-
centage with rSBA-MenC titresP1:128 or for the rSBA-MenC GMT
at year 2 (exploratory analysis).
After primary vaccination the percentage of MenC-CRM197
recipients with rSBA titres P1:8 was 50.0% for serogroups A and
W, and 75.0% for serogroup Y. At year 2, the percentages had
increased to 82.1% for serogroup A, 58.6% for W and 80.0% for Y.hSBA antibodies
Two years after primary vaccination, the percentage of subjects
in the MenACWY-TT group with persisting hSBA antibody titres
P1:8 was 86.9% for serogroup C, 91.1% for W and 87.0% for Y, while
only 23.0% retained hSBA antibody for serogroup A (Table 1). For
serogroups A and C, hSBA GMTs decreased by year 2 but remained
higher than pre-vaccination levels (Table 1 and Fig. 3).
The percentage of subjects in the MenC-CRM group with hSBA-
MenC titres P1:8 was 52.6%. The hSBA-MenC GMT reduced by
year 2 but remained higher than pre-vaccination levels (Table 1
and Fig. 3).
The exploratory group comparison indicated that antibody
persistence for serogroup C was statistically signiﬁcantly higher
in the MenACWY-TT group than in the MenC-CRM group in terms
of the percentage of subjects with hSBA titresP1:8 and the hSBA-
MenC GMT. In contrast to measurements using rSBA, few subjects
in the MenC-CRM group had antibody titresP1:8 against the other
serogroups using hSBA: 0.0% for serogroups A and W, and 22.7% for
serogroup Y.Safety
No vaccine-related SAEs were reported from the end of the pri-
mary vaccination study until the year 2 persistence visit.Discussion
This study of antibody persistence in toddlers showed that anti-
bodies as measured by rSBA persisted in the majority of subjects
vaccinated with MenACWY-TT until 2 years after vaccination.
Exploratory analyses conducted after the primary vaccination dose
indicated that the post-vaccination rSBA-MenC GMT was statisti-
cally signiﬁcantly higher in MenACWY-TT recipients than in
MenC-CRM197 recipients [6]. In-line with these results, we
observed a higher percentage of subjects with rSBA-MenC titres
P1:8 in the MenACWY-TT group compared to the MenC-CRM
group at year 2 (exploratory analysis).
The results of our study using the GSK rSBA are consistent with
other studies of MenACWY-TT persistence in adolescents and chil-
dren where the same assay was employed [12–14]. Good antibody
persistence up until 3 years after vaccination of adolescents with
MenACWY-TT has been demonstrated, while in toddlers, persisting
antibody levels have been observed to be similar or higher than
after vaccination with licensed MenC-CRM197 [13–17].
In MenACWY-TT-primed children, hSBA antibodies for sero-
groups C, W and Y persisted until year 2, whereas hSBA for sero-
group A declined rapidly (23.0%P 1:8 at year 2). Similar rapid
decay of hSBA-MenA antibodies has been observed using other
quadrivalent vaccines tested for hSBA by different laboratories:
ﬁve years after vaccination of infants with three doses of
T. Vesikari et al. / Trials in Vaccinology 3 (2014) 121–126 125MenACWY-CRM197 (Menveo™Novartis) the percentage with hSBA-
MenA P1:8 was no higher than 4% [18]. Two years after vaccina-
tion of adolescents with MenACWY-CRM197 or MenACWY-DT, the
percentage with hSBA-MenA P1:8 had decreased from 75% to
36%, and from 67% to 25%, respectively [19].
Persistence of hSBA for the other serogroups after MenACWY-
TT vaccination appeared comparable to other quadrivalent
vaccines: 2–3 years after vaccination of 2–3 year olds with a
single dose of MenACWY-DT (Menactra™ Sanoﬁ Pasteur), 14.6%
of children had hSBA P1:4 [20]; ﬁve years after 3 MenACWY-
CRM197 doses by 12 months of age, hSBA P1:8 for serogroups
C, W and Y was observed in 27–45%, 81–84% and 42–57%,
respectively [18].
In the present study we observed that rSBA antibody GMTs for
serogroups A, W and Y increased at year 2 in the control group
who had not received vaccination with these serogroups. The
percentage of subjects with rSBA titres P1:8 for serogroups A,
W and Y increased to as high as 82.1% (serogroup A) by year 2.
The observed increases in rSBA probably reﬂects the development
of natural immunity during childhood [9,21]. Natural immunity
develops through production of IgM, and rabbit complement is
thought to be activated by IgM as well as IgG [22,23]. By con-
trast, hSBA titres remained very low for serogroups A and W in
MenC-CRM197 recipients, while the percentage of children with
hSBA-MenY titres P1:8 increased to 22.7%. The increase in
hSBA-MenY titres over time may reﬂect natural exposure to sero-
group Y, which in Finland, along with other Scandinavian coun-
tries, causes a substantial proportion of invasive meningococcal
disease [24]. Thus, the GSK rSBA and GSK hSBA assays detect nat-
ural immunity differently, with the GSK rSBA assay having a
greater sensitivity than the GSK hSBA assay. It is unclear whether
natural immunity as measured by GSK rSBA represents true sero-
protection in contrast to the vaccine-induced immunity mea-
sured with this assay.
hSBA GMTs (but not rSBA GMTs) for serogroup W and Y were
also observed to increase between month 1 and year 2 in the Men-
ACWY-TT group. Similar observations have been made by other
authors after vaccination of infants with Menveo™ [25], and after
vaccination of toddlers with Menactra™ [26], possibly as a result
of avidity maturation, a slower antibody response, or a boosting
effect due to natural exposure.
Follow-up of our study cohort is planned until year 10 post-vac-
cination. At year 4, children were invited to receive a booster dose
of the same meningococcal vaccine they had received at 12–
23 months of age (results published elsewhere). We used GSK’s
rSBA until year 2 and samples collected after year 2 will be tested
at a different laboratory. Thus, the present results will not be
directly comparable with future persistence studies.Conclusions
In conclusion, 2 years after a single dose of MenACWY-TT
administered to toddlers, antibodies measured by both rSBA and
hSBA assays persisted for all serogroups A, C, W and Y, with indica-
tion of higher antibody persistence for serogroup C after vaccina-
tion with MenACWY-TT than with MenC-CRM197.Sources of support
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